Turoctocog alfaClassification: B
Drug products: NovoEight
ATC code: B02BD02
Substances: turoctocog alfa
As the substance is almost exclusively used by men, analyses on sex or gender differences have not been considered relevant.
Tuructocog alfa is a factor VIII concentrate product used in treatment of acute bleeding episodes, perioperative management and routine prophylaxis patients with hemophilia A . Hemophilia A (deficiency in coagulation factor VIII) is an inherited X-linked disease and thus affects primarily men although women also can be affected (for example because of skewed inactivation of chromosome X) . The occurrence of hemophilia A in women is very rare and data in women is not available .
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding pharmacokinetics and dosing of tuructocog alfa have been found.
No studies with a clinically relevant sex analysis regarding effects of tuructocog alfa have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of tuructocog alfa have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2020-05-20
- Vakil NH, Fujinami N, Martin-Stone S. Turoctocog alfa for the treatment of hemophilia a. Pharmacotherapy. 2014;34(10):1091-101. PubMed
- Mehta P and Reddivari AKR. Hemophilia, in StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
- NovoEight (turoctocog alfa). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2020-03-12, cited 2020-05-20].
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk
Reviewed by: Carl-Olav Stiller, Diana Rydberg
Approved by: Karin Schenck-Gustafsson